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ABSTRACT: 
BACKGROUND- Platelets for transfusion stored at room temperature (RTP) have a 
short shelf-life and diminished hemostatic function. Cold stored platelets (CSP) have 
a longer shelf-life and may be more hemostatically active than RTP. However, the 
manufacturing techniques used to produce CSP are not standardized. To investigate 
whether the CSP manufacturing process influences functional characteristics of 
CSP, we systematically reviewed published CSP articles. 
METHODS- MEDLINE and EMBASE databases were searched for articles 
describing the functional or clinical characterization of CSP published after January 
2000. Data relating to manufacturing technique and CSP characteristics in 
shortlisted articles were recorded using a standardized proforma.  
RESULTS- From a total of 1521 articles identified using the search terms, 106 
articles underwent full text review, and 33 were shortlisted for full analysis. Marked 
heterogeneity in manufacturing and functional testing of CSP were identified. A 
greater relative proportion of articles collecting CSP by apheresis reported higher 
hemostatic activity than RTP compared to whole blood-derived CSP. A greater 
relative proportion of articles reporting CSP suspended in plasma alone reported 
higher hemostatic activity than RTP compared to CSP suspended in plasma plus 
platelet additive solution. There was no consistent trend suggesting that other 
manufacturing variables, such as time from collection to cold storage, influenced the 
functional characteristics of CSP. 
CONCLUSION- CSP may have superior hemostatic activity than RTP and therefore, 
may be more effective at controlling bleeding. However, we highlight that 
manufacturing technique also influences hemostatic activity and may have an 
important impact on clinical efficacy and safety of CSP.  
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INTRODUCTION  
 
The incidence of platelet transfusion increased by 25% in the developed world 
between 2007-2008 and 2014-2015, predominantly because of wider use in 
hematological malignancies, which currently accounts for approximately two thirds of 
all platelets used.1  Supplying platelets is more logistically challenging than other 
blood components because with almost all current specifications, platelets require 
storage at 22°C with continuous agitation (room temperature platelets; RTP). This 
requires transfusion laboratories to provide a platelet agitator and incubator, thereby 
increasing costs, logistical burden and equipment footprint. Since room temperature 
storage also increases the risk of bacterial contamination of platelets, bacterial 
monitoring of RTP was adopted universally in many countries, further increasing 
healthcare costs. Even with these measures, the maximum shelf-life of standard 
RTP is between three and five days in most countries, but may be extended to seven 
days with point-of-release bacterial testing.  The function of RTP also declines during 
storage because of metabolic changes that impair platelet activation responses, 
known as the “platelet storage lesion”, which is only partially reversible after 
transfusion.2-4  
 
The current use of RTP originated more than four decades ago when several 
landmark studies compared RTP with platelets stored at 4C (cold stored platelets; 
CSP).5-7 In the first of these studies, autologous Chromium-51 labelled CSP stored 
ex vivo for 18 hours transfused to healthy volunteers had a lower incremental yield 
and a reduced circulating half-life compared with RTP controls.5 This study further 
reported the effect of storage of platelets at 22°C for up to six days and suggested  
that the yield and half-life of the platelets after transfusion deteriorated with 
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increasing storage interval but with a rapid deterioration in platelets stored between 
three and five days.5 The finding that CSP had unfavorable pharmacokinetic 
characteristics compared with RTP was reproduced in subsequent studies in healthy 
volunteers and patients with thrombocytopenia.7-10 In studies in which functional 
outcomes were assessed, the bleeding time (BT) corrected more after infusion of 
autologous CSP than with RTP in aspirin-treated volunteers,6,7 and in 
thrombocytopenic patients.7 However, in other functional studies, there were no 
differences between CSP and RTP. 8,10,11 
 
During the decade after these studies, many blood transfusion laboratories stocked 
both RTP and CSP as a dual inventory. However, since the main indication for 
platelet transfusion at this time was to prevent bleeding in thrombocytopenic 
patients, the longer half-life RTP products were favored. Since dual inventories of 
both RTP and CSP increased complexity and cost, transfusion practice in most 
centers subsequently altered to a single stock of RTP. Interest in CSP has re-
emerged because platelet transfusion is increasingly used to treat acute bleeding, 
particularly following trauma. In these settings where long term prevention of 
bleeding is seldom required, the increased hemostatic function of CSP may be 
clinically advantageous whereas the reduced circulating half-life after transfusion is 
of less importance. The resurgence in studies relating to CSP has been summarized 
in several recent reviews which highlight that CSP consistently show superior 
hemostatic activity by enabling more effective primary hemostasis and by supporting 
stronger fibrin clot formation compared to RTP.12-15 
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Although together these data create a compelling case for further clinical study of 
CSP, one important criticism of recent studies is that the CSP manufacturing 
variables such as collection method, storage medium, and the timing of collection 
and storage differs between studies. Therefore, the potential impact of 
manufacturing process on the characteristics of CSP, remains an important area of 
uncertainty. In order to help resolve this, and to help promote standardization of a 
future CSP product for clinical study, we have reviewed the current literature with 
particular focus on manufacturing variables. The review is divided into three core 
areas: 
1. Manufacturing variables used to generate CSP products. 
2. The effect of manufacturing variables on the hemostatic function of CSP. 
3. The efficacy and safety of CSP in clinical studies. 
 
METHODS 
 
Searches were conducted in January 2018 using MEDLINE and EMBASE 
databases. The search terms used were: cold AND stor* AND platelet*; "cold 
platelet*"; refrigat* AND platelet*;("4C" OR "4°C" OR "4 C") AND platelet*. In 
addition, a search using the Medical Subject Headings (MeSH) “cold temperature” 
and “blood platelets” was performed in both databases, mapped to the phrase “cold 
platelet*". 
 
After removal of duplicates, article abstracts were analysed if they reported platelets 
that were stored in cold, 4C or refrigerated conditions and fulfilled all of the following 
inclusion criteria: article published in a peer reviewed journal, reported either 
apheresis-derived platelets (AP) or whole blood-derived (WBD) platelets, human or 
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non-human studies, and full text available via institutional accesses (University of 
Bristol / Defence Medical Services Library Service / British library). 
 
Articles were excluded if they met any of the following criteria: background articles or 
reviews, abstract only, non-English language articles, platelets cold stored for less 
than 18 hours, platelets stored in the cold as whole blood (WB), articles published 
prior to January 2000, or no functional assessment of stored platelets 
 
The articles were screened and shortlisted using Rayyan, a web and mobile app for 
systematic reviews by two individuals who were blinded to the decisions of the other 
reviewer.16 Both sets of shortlisted articles were then compared and a final selection 
for full text review was agreed. CSP experts were then consulted, and the 
bibliographies of reviews and primary articles were examined to ensure all relevant 
articles had been included. To enable focus on current manufacturing practice, 
literature describing the functional assessment of CSP was restricted to publication 
dates from January 2000 to January 2018. Manufacturing and functional testing 
variables were extracted from the screened articles and recorded using a 
prespecified proforma.  
 
RESULTS 
 
A total of 1521 articles were identified (635 in MEDLINE and 886 in EMBASE) from 
the search terms described, which included 205 duplicates identified using Endnote 
duplicate software (Figure 1). Of the remaining 1316 articles, manual inspection of 
the titles and abstracts identified a further 267 duplicates and a further 943 articles 
that were excluded for not meeting the eligibility criteria. No additional articles were 
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identified following consultation with experts in the field or bibliographic review. A 
total of 106 articles subsequently underwent full text review of which 33 shortlisted 
articles were confirmed to have met the eligibility criteria and underwent full analysis. 
 
Article characteristics 
CSP articles identified in the initial shortlist were published at a rate of 12.6 per year 
between January 1970 and January 2008, thereafter, increasing rapidly to 72 articles 
per year in 2017 (Figure 2). CSP publications spanned all five continents with North 
America and Europe most represented. North American articles predominantly 
reported use of AP whereas European centers predominantly reported WBD 
platelets.  
 
Study designs 
Of the 33 shortlisted articles that met the eligibility criteria,17-49 CSP were compared 
to RTP in 28 (85%) and to temperature-cycled platelets (TCP) in two (6%).37,48 No 
CSP comparisons were performed in three (9%) of the articles.17,22,47 A total of 24 
(73%) of the shortlisted articles reported analyses of CSP exclusively ex vivo, 
without administration to a recipient.18-24,26-36,38,40-42,45,46,49 Of the remaining nine 
(26%) articles that reported analyses of CSP that were administered to a recipient, 
two articles reported autologous human donor-recipient transfusion,18,48 five articles 
reported human to non-human xenotranfusions,25,37,39,43,44 one article reported a non-
human autologous donor-recipient model,17 and one article reported a service 
evaluation of a clinical CSP product.47  
 
1. Manufacturing variables used to generate CSP products 
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Platelet preparation 
Seventeen of the shortlisted articles (52%) were collected as AP using devices 
manufactured by Gambro (1 article),38 Haemonetics (3 articles)18,35,43 and Terumo (9 
articles),20,36,37,40,42,45-48 with no manufacturers identified in the remaining 4 
articles.33,39,41,44 In the articles that reported use of AP, CSP were collected into acid-
citrate-dextrose (7 articles).20,38,40,42,45,46,48 The remaining 10 AP articles did not 
specify an anticoagulant.18,33,35-37,39,41,44,47 CSP were obtained as an “experimental 
mononuclear cell collection by-product” (EMBP) in one study and were classified as 
AP in this review (Table 1).33  
 
Of the 19 (58%) articles in which the CSP products were WBD, 10 (53%) articles23-32 
were produced by buffy coat (BC) preparations and nine (47%) were produced via 
platelet rich plasma (PRP) preparations.17-22,26,36,39 The predominant anticoagulant 
for WBD platelets was citrate-phosphate-dextrose which was reported in 10 (53%) 
articles (Table 1).19,23,24,26,28-32,36 The two articles that reported the use of CSP from 
animal origin utilized PRP-derived platelets.18,25 Three articles reported both AP and 
WBD CSP products.18,20,39  
 
Platelet storage medium and bag 
The CSP suspension medium was reported in 28 (85%) of the shortlisted articles. Of 
these, the suspension medium was plasma alone in 19 (68%),17-25,40-48  plasma plus 
platelet additive solution (PAS) in 11 (39%),26-32,38,40,41 and two articles reporting of 
both media.40,41 A total of 12 (36%) articles described supplementation of the 
suspension medium with additives (Table 1).17-19,21,23-25,27,38,39,49 Storage bag 
specification details were included in 21 (64%) articles, of which 20 (95%) reported 
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use of gas permeable bags.17,18,21,23,24,26-29,33,34,36-38,40,42,43,45,46 The remaining article 
reported gas impermeable tubes.20 Of the 20 articles reporting storage bags, there 
were 17 different types of storage bags produced by ten different manufacturers. 
 
Time interval between platelet donation and cold storage 
The time interval (t) between platelet donation and the start of cold storage was 
specified in 20 (60%) of the shortlisted articles.17,18,21-23,25-30,33,35,40-42,44,45,47,48 The 
time interval was reported as being within 6 hours of donation (t<6h) in 10 articles, 
17,18,22,23,26,40-42,45,48  between 6 and 24 hours in three articles (6<t<24h),28,29,35 and 
more than 24 hours (t>24h) in seven articles (Figure 3).21,25,27,30,33,44,48 
 
Storage conditions and monitoring 
A total of 32 (97%) shortlisted articles, reported a CSP storage temperature of 4°C 
and one reported a temperature of 10°C,39  which was not considered for any 
grouped analyses of CSP. Agitation of CSP was reported in 28 (85%) articles, no 
agitation was used in two (6%) articles,35,38 and the remaining two (6%) articles 
compared agitated versus non-agitated CSP.34,42 CSP were monitored for bacterial 
contamination in seven (21%) articles.28,29,34,39,44,47,48  
 
Manufacture of RTP used as a comparator for CSP 
In all of the 29 (89%) articles in which RTP were used as a comparator to CSP, the 
RTP were stored at 22±2 °C with agitation, but collection and storage methods 
varied.18-21,23-46,48,49 However, in 28 articles, the collection and storage methods for 
RTP were the same as the CSP test product.  In the remaining article, RTP were 
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stored using a gas permeable bag whereas CSP were stored in polypropylene 
tubes.43  
 
2. The effect of manufacturing variables on the hemostatic function of CSP. 
Hemostatic function of CSP was tested in all 33 shortlisted articles using a wide 
range of methods, often with multiple methods reported in the same article (Table 
2).17-49 For reviewing purposes, hemostatic function assays were classified into three 
categories: basal activation, activation responses, and dynamic hemostatic function. 
Tests to measure the basal activation of CSP  were performed in 19 (58%) articles 
and included the use of flow cytometry to measure platelet surface activation 
markers such as P-selectin, phosphatidylserine or activated IIb3 integrin (PAC1 
antibody binding) in the absence of agonist stimulation.18,20,21,23,25,27,29,31,35-37,39,40,42-
44,46,48,49 In 21 (61%) articles, tests were performed to measure the activation 
responses of CSP to stimulating agonists, using light transmission aggregometry 
(LTA) in 17 (52%) articles,18,19,21-23,25,26,30,33,35,37-39,41,46,48,49 and electrical impedance 
aggregometry (EIA) in four (12%) articles.41,43-4 In six (18%) articles, CSP activation 
responses were also measured using flow cytometry after agonist stimulation to 
monitor increases in surface activation markers.19,21,27,33,46,49 Two articles measured 
CSP activation responses by measuring thrombin generation.36,46 Twelve (36%) 
articles tested the dynamic hemostatic function of CSP by measuring clot formation 
and clot strength using viscoelastic tests (e.g. rotational thromboelastometry 
[ROTEM], thromboelastography [TEG], rheometry)30,35,40-42,45,47 or by measuring 
CSP adhesion to a solid surface under shear flow conditions.20-23,41,46,49  
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Evaluation of the physical characteristics of CSP were reported in 16 (48%) articles 
using visual inspection or microscopy to identify features such as swirl, aggregate 
formation and the ultrastructure of platelets.17-19,21,23,25,28-30,35,37,39,41,42,46,47 Analysis of 
biomarkers in CSP supernatant during storage was reported in 13 (39%) 
articles.19,24,25,27,28,31,32,38,40,44,46-48  In the articles that described transfusion of CSP 
into human or animal recipients, one (3%) reported BT in recipients as a clinical 
marker of efficacy.17 
 
Manufacturing techniques and laboratory test results in CSP versus RTP 
In view of the heterogeneity of the 33 shortlisted articles, potential relationships 
between manufacturing variables and functional test results of CSP (stored at 4°C) 
compared with RTP were considered only against three main manufacturing 
variables: AP versus WBD platelets (Table 3), suspension in plasma versus plasma 
plus PAS (Table 4), and storage within 6 hours of collection (t<6h) versus storage 
after 6 hours (t>6h) of collection (Table 5).  
 
Basal platelet activation 
Of the 18 (53%) articles in which basal activation of CSP was compared to RTP, six 
(32%) articles showed an increase in basal platelet activation in CSP (increased 
baseline platelet P-Selectin exposure in five; increased platelet phosphatidylserine 
exposure in four; increased PAC 1 binding in two).31,35,42-44,48 By contrast, 12 (58%) 
articles showed no difference in basal platelet activation between CSP and RTP 
(Table 3).18,20,21,23,25,27,29,36,37,40,46,49 
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Manufacturing variables were not reported in all of these articles. However, a higher 
relative proportion of the six articles that did report higher basal activation with CSP 
used AP (5/6, 83%), plasma suspension (4/5, 80%) and t>6h (2/3, 66%). By 
contrast, a higher relative proportion of the 12 articles that reported no difference 
between CSP and RTP used WBD (8/12, 67%) platelets, suspended in plasma plus 
PAS (4/9, 44%) and stored within 6 hours (t<6h) after collection (6/10, 60%; Table 
3). 
 
Platelet activation responses 
Of the 20 (60%) articles in which activation responses of CSP were compared with 
RTP, 14 (70%) articles showed increased activation responses in CSP (increased 
LTA responses in eight;21,26,30,33,38,41,46,48 increased EIA responses in four;42,44-46 
increased platelet surface activation markers after agonist stimulation in three,21,33,46 
and increased thrombin generation in two).36,46 One article reported increased 
activation responses in RTP compared to CSP after platelets were dual-stimulated 
with both ADP and collagen, but increased activation responses in CSP after 
stimulation with either ADP or collagen alone.37 The remaining six (30%) articles 
showed no difference in activation responses between CSP and RTP (Table 
4).22,23,25,27,35,49 
 
Manufacturing variables were not reported in all of these articles. However, a higher 
relative proportion of the 14 articles that reported increased CSP activation 
responses used AP (10/14, 71%), suspended in plasma (7/10, 70%) and stored 
within 6 hours (t<6h) after collection (6/10, 60%). By contrast, a higher relative 
proportion of the six articles that reported no difference between CSP and RTP used 
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WBD (5/6, 83%) platelets, suspended in plasma (3/5, 60%) and stored more than 6 
hours (t>6h) after collection (3/5, 60%; Table 4). 
 
Platelet dynamic hemostatic function 
Of the 12 (36%) articles in which dynamic hemostatic function of CSP was compared 
with RTP, six articles showed increased dynamic hemostatic function in CSP 
(increased viscoelastic strength in four;35,40,42,45 increased aggregation under shear 
conditions in one,46 and increased clot strength by rheometry in one).41 The 
remaining six articles showed no difference in dynamic platelet hemostatic function 
between CSP and RTP (Table 5).21,23,30,32,47,49  
 
Manufacturing variables were not reported in all of these articles. However, a greater 
relative proportion of the six articles that reported higher dynamic hemostatic 
function with CSP used AP (6/6, 100%), suspended in plasma (3/5, 60%) and stored 
within 6 hours (t<6h) of collection (5/6, 83%). By contrast, five of the six articles that 
reported no difference in dynamic hemostatic function used WBD (83%) 
platelets.21,23,30,32,49 Amongst the articles with no difference in dynamic hemostatic 
function, the relative proportions of articles with suspension in plasma versus plasma 
plus PAS and those with storage within 6 hours (t<6h) of collection versus storage 6 
hours after collection (t>6h) were the same (Table 5).21,23,30,32,47,49 
   
Within-study comparisons of CSP manufacturing variables 
Of the 33 shortlisted articles, 11 (33%) compared at least two CSP products within 
the study, that were manufactured in different ways.17-19,21,25,34,36,40-42,49 Six of these 
articles reported the effect of additives in the CSP storage medium. One article that 
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used glucose-free medium with antimycin A to suppress CSP metabolism reported 
increased CSP basal P-Selectin expression and adhesion to vWF and fibrinogen 
compared to HEPES-Tyrode’s medium.49 Of the remaining five articles that 
compared additives, one article reported no difference between Thrombosol and 
amiloride plus sodium nitroprusside19; three articles reported no effect from UDP-
Galactose, used to galactosylate the platelets.18,21,25 In an autologous baboon 
transfusion model, thrombopoietin or cytochalasin B plus ethylene glycol tetraacetic 
acid (cyto-EGTA) did not alter the CSP recovery or survival.17  
 
In one article, microaggregates were observed in CSP suspended in plasma, but not 
in plasma with PAS (30:70).40 In a similar article, CSP in plasma plus PAS (30:70) 
formed clots with less crosslinking but similar stiffness compared to control CSP in 
plasma alone.41 Two articles reported no differences between agitated and non-
agitated CSP.34,42 One article reported that thrombin generation with apheresis-
derived CSP peaked earlier than with WBD CSP, while all other thrombin generation 
profile parameters and functional characteristics remained comparable.36   
 
3. The efficacy and safety of CSP in clinical studies  
Of the 33 shortlisted articles, nine articles (27%) reported CSP transfusion to human 
or animal recipients followed by enumeration or functional characterization of 
circulating platelets obtained from the recipient after transfusion.17,18,25,37,39,43,44,47,48  
 
In a single, open-label phase 1 study, four healthy human volunteers received 
radiolabelled autologous apheresis-derived CSP stored for 48 hours that were either 
galactosylated with UDP-galactose or untreated.18 The mean survival of the 
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galactosylated CSP (2.2 ± 0.9 (SD) days) were the same as non-galactosylated CSP 
controls (2.9 ± 0.1 days), but both CSP products had shorter survival than RTP (>6 
days).18  
 
In the second study, healthy volunteers also received radiolabelled autologous 
platelet transfusions.48 In this study, double collections of AP suspended in plasma 
were stored as RTP, CSP, or TCP (TCP – 24 hours at room temperature followed by 
continuous cycling between 11 hours at 4°C and 1 hour at 37°C) for 7 days.  Paired 
comparisons between RTP and TCP or TCP and CSP were performed through 
radiolabelling with either 51Chromium or 111Indium before re-infusion and calculation 
of recovery and survival. CSP were reported to have the poorest recovery with TCP 
being better than CSP, but TCP not being equivalent to RTP.48 
 
One article described the implementation of a CSP programme at a single US centre 
for trauma patients.47 The article describes administration of 21 CSP units (all AP, 
suspended in plasma and stored within 6 hours) to 20 recipients. In this programme, 
80.9% of CSP were discarded either because of the presence of visible platelet 
aggregates or because CSP had reached the end of the 72-hour shelf-life (as 
stipulated by the 2015 Food and Drug Administration (FDA) license).47 No functional 
or outcome data was reported in this article. 
 
Of the six articles reporting CSP transfusion to animal recipients, a single article 
compared autologous transfusion in baboons with CSP stored with either 
thrombopoietin, cyto-EGTA, or no additives.17 The platelet recovery and survival was 
the same in the treatment groups and the prolonged BT caused by aspirin treatment 
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corrected similarly in thrombopoietin-treated and no-additive CSP models.17 Five 
articles reported human CSP transfusion into immunosuppressed mice or 
rats.25,37,39,43,44 In all cases, CSP had reduced recovery and survival compared to 
RTP. There were no adverse events from CSP in any of the human or animal CSP 
recipients, including bacterial contamination or sepsis.  
 
DISCUSSION  
A striking feature of this review was that amongst the 33 shortlisted articles, there 
was wide variation in the manufacturing techniques for CSP. There were also 
marked differences in the way that different CSP products were functionally 
evaluated. Most of the articles compared CSP from a single manufacturing process 
to RTP controls rather than comparing CSP prepared from different manufacturing 
techniques. Few articles reported transfusion of CSP into recipients, and very limited 
data described the functional characteristics of CSP after transfusion.  
 
Despite these limitations, several broad observations can be drawn from this 
analysis. First, AP and WBD platelets were both common ways of preparing CSP in 
the shortlisted articles.  Articles reporting AP CSP usually showed higher hemostatic 
activity than RTP controls whereas articles reporting WBD CSP usually showed no 
difference to RTP. Second, suspension of CSP in plasma alone was more common 
than suspension in plasma plus PAS in the shortlisted articles. Articles reporting 
CSP suspended in plasma alone usually showed higher hemostatic activity than 
RTP controls. Articles reporting CSP suspended in plasma plus PAS usually showed 
no difference to RTP but less platelet aggregate formation. Third, cold storage within 
6 hours (t<6h) and cold storage after 6 hours (t>6h) of platelet collection were both 
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common techniques in the reported articles. There was no consistent trend between 
time to cold storage and hemostatic activity of CSP versus RTP. Fourth, there was 
no consistent trend suggesting that other manufacturing variables such as agitation 
versus non-agitation, additive versus no additive, or storage bag specification 
influenced the functional characteristics of CSP. 
 
The observation that most articles who used AP products reported higher hemostatic 
activity in CSP than RTP controls, whereas articles who used WBD platelets saw no 
difference between CSP and RTP controls has not been demonstrated previously. 
Differences in platelet activation levels among AP, PRP, and BC-derived platelets 
have been reported pre-storage; for example, platelet basal activation exposure 
detected by measuring CD62P, GPIIb/IIIa activation, and GPIb shedding have all 
been shown to occur less frequently with the collection of AP compared to PRP-
derived platelets.50-52 A proposed explanation is that less mechanical manipulation is 
required for preparation of AP compared to WBD, potentially leading to lower levels 
of ex vivo platelet activation and depletion of pro-activation mediators such as 
platelet granules and surface receptors50,51 However, following AP and WBD platelet 
storage at room temperature, no discernible differences in clinical hemostatic 
efficacy, recovery, or safety endpoints have been proven.50,51  The possible 
differences between AP and WBD CSP could result from the varying degrees of pre-
storage activation being preserved in CSP, whereas in RTP the differences 
disappear as the platelet storage lesion evolves.  
 
The observation that most articles reporting CSP suspended in plasma alone 
showed higher hemostatic activity than RTP controls whereas CSP stored in plasma 
  18 
plus PAS were usually no different than RTP controls is similar to those reported by 
Van Hout et al. in vitro.53 In this article whole blood was reconstituted using 
components: packed red blood cells, plasma, and either RTP in plasma alone or 
RTP suspended in plasma and PAS (30:70). Response to agonists was reduced in 
WB reconstituted using RTP in plasma plus PAS compared to RTP in plasma 
alone.53 It has also been shown in CSP that the addition of PAS to plasma, reduces 
aggregate formation in the storage bag as well as fibrin crosslinking within the clot in 
vitro.40,41 This result may be due to reduced binding of FXIIIa and fibrinogen in CSP 
suspended in plasma plus PAS compared to plasma alone.40,41 Practically there are 
pros and cons of both CSP stored in plasma alone versus CSP stored in plasma plus 
PAS. For example, 100% plasma CSP are more likely to form aggregates, which in 
clinical practice contributes to high wastage.47 Conversely, the addition of PAS to 
plasma not only may result in reduced hemostatic function of CSP, but also 
increases the crystalloid volume transfused during the resuscitation, potentially 
resulting in inferior clinical outcomes.53  
 
The observation of no consistent trend between time to cold storage and CSP 
hemostatic activity versus RTP is consistent with the outcome of a recent study that 
was published after the searches for this review were performed.  This reported that 
refrigeration of platelets after four days storage at room temperature can restore 
hemostatic function to a comparable level as CSP cooled the day after collection.54 
This article would support the finding that the time from collection to cold storage is 
the least critical variable of the three analyzed here. It is important to highlight 
however, because only 60% of articles reported the time from collection to cold 
storage, any real differences in hemostatic function may have been lost in this 
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analysis. Indeed, an explanation for the observed trend of higher hemostatic activity 
seen in apheresis-derived CSP could in part be due to the compound effect of early 
storage in the cold and collection by apheresis and conversely, delayed cooling with 
WBD CSP. It would be important to consider if the time to cooling of platelets 
following collection independently influences CSP functional outcomes when 
performing further CSP studies and clinical trials.  
 
Limitations of this analysis 
The most significant limitation of this review is the heterogeneity of the articles 
analyzed. There was also incomplete reporting of important manufacturing variables, 
making the number of articles available for comparison small. Variation in the 
methods used to assess the function of CSP required grouping of methodologies to 
enable any conclusions to be drawn; although these groups generalize complex 
assays their principles are similar. The lack of functional data is most apparent in the 
clinical studies, in which no studies directly compared RTP and CSP clinical 
outcomes. The last article comparing clinical outcomes in patients following RTP 
versus CSP transfusion was published 38 years ago, and there is a real need for 
clinical trials to understand the impact of CSP in patient populations.9  
 
CONCLUSIONS 
This review highlights that CSP may have superior hemostatic activity compared to 
RTP and therefore, may be more effective clinically in some applications, particularly 
in acute bleeding where sustained survival of transfused platelets in recipients is not 
essential. However, we also highlight that manufacturing technique influences 
hemostatic activity and may have an important impact on clinical efficacy and safety 
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of CSP. Operational considerations are also present which may potentially influence 
manufacturing techniques. The systems worldwide for provision of blood and its 
components vary hugely from small scale centres to large scale, nationalized 
systems. It is therefore unlikely that a single CSP manufacturing methodology will be 
universally adopted without robust evidence of benefit.  
 
We highlight that there is an unmet need for randomised clinical trials investigating 
the efficacy of CSP compared to current RTP products in each of the clinical groups 
in which platelet transfusion is frequent, particularly trauma, cardiothoracic surgery 
and hemato-oncology patients. It is essential for future RCTs to examine clinically 
relevant endpoints such as morbidity and mortality, or healthcare cost outcomes 
rather than laboratory endpoints. Moreover, significant efforts should be made to 
standardise manufacturing variables across trials and that CSP products should be 
developed in collaboration with blood bank services to ensure that findings can be 
readily translated to healthcare services. 
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FIGURE LEGENDS 
Figure 1: Results from the literature searches, screening and full text review. 
 
Figure 2: Number of published articles by year. Data represent the total number of 
articles identified in the initial search after removal of duplicates (n=1049).  
 
Figure 3: Time taken from donation to the start of cold storage. Data are from 21 
articles in which time from donation to storage was reported and are subdivided 
according to method of manufacture of CSP: AP- Apheresis derived; WBD PRP – 
Platelet rich plasma; WBD BC-buffy coat.  
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TABLE TITLES 
Table 1: Platelet suspension medium, anticoagulant and additives.  
 
Table 2: Functional and quality tests reported in the shortlisted articles.  
 
Table 3: Baseline platelet activation markers in CSP compared to RTP.  
 
Table 4: Activation response to agonist stimulation in CSP compared to RTP.  
 
Table 5: Dynamic hemostatic function in CSP compared to RTP.  
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Table 1 
 AP  WBD BC WBD PRP 
Total (n=33) 17 10 9 
Anticoagulant 
Acid-citrate-dextrose solution A 
(ACD)  
720,38,40,42,45,46,4
8 
0 317,20,22 
Citrate-phosphate-dextrose (CPD) 0 823,24,26,28-32 
 
219,36 
 
Citrate 0 0 126 
 
Not reported  1018,33,35-
37,39,41,43,44,47 
225,27 318,21,39 
Suspension medium  
Plasma 1018,40-48 323-25 617-22 
Plasma and PAS 2 PAS40,41  
1 PAS III M39 
1 Tyrodes 38 
 
1 PAS26 
3 T-SOL27-29 
3 SSP+30-32 
0 
Not reported or other medium 533-37 0 136 
Additives 
ThromboSol (LifeCell Corp.)  0 323,24,27 1*19  
Trehalose  238,39 0 0 
Modifiers of Galactosylation  118 125 218,21 
Amiloride and Sodium Nitroprusside 0 0 119 
Thrombopoeitin 0 0 117 
Glucose free medium + antimycin A 0 0 149 
Cytochalasin B and L EGTA-AM  0 0 117 
Where >1 platelet origin or manufacture method was used, all methods are described. * ThromboSol 
without Ticlopidine. 
 
 
  24 
Table 2 
 
TEST AP WBD BC WBD PRP 
BASAL PLATELET ACTIVATION 
Platelet surface markers by flow 
cytometry, unstimulated (n=22) 
1118,34-
37,39,40,42,44,46,48 
525,27,29,31,32 818-22,36,39,49 
PLATELET ACTIVATION REPONSE 
Light transmission aggregometry  
(n=17) 
918,33,35,37-
39,41,46,48 
4 23,25,26,30 519,21,22,39,49  
Impedance aggregometry  
(n=4)  
442,44-46 0 0 
Activation responses by flow 
cytometry following agonist 
stimulation 
(n=6) 
2 33,46 127 319,21,49 
Thrombin generation test  
(n=1) 
136 0 0 
DYNAMIC HEMOSTATIC FUNCTION 
Viscoelastic test 
(n=6) 
535,40,42,45,47 130 0 
Adhesion in shear conditions 
(n=7) 
241,46  123 420-22,49 
Rheometry  
(n=1) 
141   
OTHER 
Physical characteristics  
(n=15) 
718,37,39,41,42,46,47  523,25,28-30 517-19,21,39 
Hypotonic shock response 
(n=4) 
218,35 
1 
30 
2 
18,19 
Supernatant biomarkers 
(n=13) 
638,40,44,46-48   624,25,27,28,31,32  119 
In vivo function and/or recovery and 
survival  
(n=8) 
618,37,39,43,44,48  125 317,18,39 
Methods used to assess CSP function are subdivided according to whether the CSP were apheresis 
derived (AP), whole blood derived and buffy coat (WBD BC) or whole blood derived and platelet rich 
plasma WBD PRP). 
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Table 3 
 
Reference 
MANUFACTURING VARIABLE BASAL PLATELET ACTIVATION 
AP  
(Y/N) 
Plasma 
alone 
(Y/N) 
Cooling 
<6hrs 
(Y/N) 
 
More with 
RTP 
No 
difference 
More with 
CSP 
27 N N N  +  
23 N Y Y  +  
49 N N -  +  
29 N N N  +  
21 N Y N  +  
18 Y  Y Y  +  
25 N Y N  +  
35 Y - N   + 
43 Y Y -   + 
42 Y Y Y   + 
44 Y Y N   + 
46 Y Y Y  +  
31 N N -   + 
36 Y - -  +  
36 N - -  +  
37 Y - Y  +  
40 Y Y Y  +  
40 Y N Y  +  
20 N Y -  +  
48 Y Y -   + 
The studies listed in chronological order have been classified according to whether basal activation was 
more with CSP, no difference between CSP and RTP or more with RTP. The main manufacturing 
variable have been classified as follows: apheresis platelets (AP) Y versus whole blood derived (N); 
suspended in plasma alone (Y) versus plasma plus additive solution (N); cooled <6 hours after 
collection from donor (Y) versus more than 6 hours (N).  
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Table 4 
 
Reference 
MANUFACTURING VARIABLE PLATELET ACTIVATION REPONSE 
AP  
(Y/N) 
Plasma 
alone (Y/N) 
 
Cooling 
<6hrs (Y/N) 
 
More with 
RTP 
No 
difference 
More with 
CSP 
27 N N N  +  
23 N Y Y  +  
33 Y - N   + 
49 N N -  +  
21 N Y N   + 
26 N Y Y   + 
25 N Y N  +  
38 Y - -   + 
35 Y - N  +  
22 N Y Y  +  
42 Y Y Y   + 
44 Y Y N   + 
45 Y Y Y   + 
30 N N N   + 
36 Y - -   + 
36 N - -   + 
37 Y - Y +*  + 
40 Y N Y   + 
46 Y Y Y   + 
41 Y N Y   + 
48 Y Y -   + 
Data are presented in the same way as Table 4 but describe the results of tests to measure platelet 
activation response. *Dual agonist stimulation (ADP and Collagen).  
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Table 5 
 
Reference 
MANUFACTURING VARIABLE DYNAMIC HEMOSTATIC FUNCTION  
AP or 
WBD 
Plasma 
alone 
(Y/N) 
Cooling 
<6hrs 
(Y/N) 
 
More with 
RTP 
No 
difference 
More with 
CSP 
23 N Y Y  +  
49 N N -  +  
21 N Y N  +  
35 Y - N   + 
42 Y Y Y   + 
45 Y Y Y   + 
30 N N N  +  
46 Y Y Y   + 
40 Y N Y   + 
41 Y N Y   + 
47 Y Y Y  +  
32 N N -  +  
Data are presented in the same way as table 4 but describe the results of tests to measure platelet 
dynamic hemostatic function. 
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